Literature DB >> 6873134

Effect of ibopamine on peripheral haemodynamics.

C Longhini, G F Musacci, L Ansani, T Toselli, M Artioli, L Bianco, P Ghirardi.   

Abstract

Peripheral haemodynamics was studied in healthy volunteers by strain gauge plethysmography after administration of ibopamine (IB), diisobutyric ester of N-methyl-dopamine, an orally active dopaminergic agonist. Seven subjects received a single oral dose of ibopamine of 150 mg and 6 received a daily dose of 150 mg (50 mg t.i.d.) for 5 consecutive days. Arterial resting blood flow and venous capacity increased and peripheral resistance decreased significantly. Six further subjects were then studied; 3 h after an oral dose of ibopamine 150 mg, the parenteral administration of Sulpiride 50 mg, a specific vascular dopaminergic antagonist, was found significantly to counteract its peripheral activity. Heart rate and arterial blood pressure were never affected and tolerability was good.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6873134     DOI: 10.1007/bf00542205

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Peripheral pre- and post-synaptic dopamine receptors: are they different from dopamine receptors in the central nervous system?

Authors:  L I Goldberg; J D Kohli
Journal:  Commun Psychopharmacol       Date:  1979

2.  Primary hypertension refractory to triple drug treatment: a study on central and peripheral hemodynamics.

Authors:  O Andersson; L Hansson; R Sivertsson
Journal:  Circulation       Date:  1978-10       Impact factor: 29.690

3.  Renal effect of SB 7505: a double-blind study.

Authors:  G F Melloni; G M Minoja; G Scorazzati; R Bauer; B Brusoni; P Ghirardi
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

4.  [Effects of an orally administered dopamine derivative on renal excretion].

Authors:  P Ghirardi; R Bauer; B Brusoni
Journal:  Nouv Presse Med       Date:  1980-02-09

5.  Double-blind haemodynamic study of a new dopamine derivative (diisobutyric ester of N-methyl-dopamine) orally active in chronic congestive heart failure.

Authors:  P Mengeot; F Piette; M Mirgaux
Journal:  G Ital Cardiol       Date:  1981

6.  Effectiveness of ibopamine in the management of ascitic liver cirrhosis--a controlled study v placebo and frusemide.

Authors:  G F Melloni; G M Minoja; R Melloni; E Piatto; E Scarazzati; R Bauer; P Ghirardi
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

7.  Noninvasive evaluation of the effects of oral ibopamine (SB 7505) on cardiac and renal function in patients with congestive heart failure.

Authors:  L Dei Cas; C Manca; B Bernardini; G Vasini; O Visioli
Journal:  J Cardiovasc Pharmacol       Date:  1982 May-Jun       Impact factor: 3.105

8.  Non-invasive evaluation of left ventricular function through systolic time intervals following oral administration of SB 7505 in man.

Authors:  L Dei Cas; C Manca; G Vasini; M Mansour; B Bernardini; O Visioli
Journal:  Arzneimittelforschung       Date:  1980

9.  Ibopamine (SB 7505) in normal subjects and in chronic renal failure: a preliminary report.

Authors:  S Stefoni; L Colì; G Mosconi; R Prandini
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

10.  Long-term treatment of chronic renal insufficiency with Ibopamine (SB 7505), a new orally active dopamine-related drug.

Authors:  S Stefoni; D Docci; A Vangelista; G Mosconi; L Colí; R Prandini
Journal:  Clin Nephrol       Date:  1982-10       Impact factor: 0.975

  10 in total
  8 in total

1.  Early cardiovascular changes with ibopamine: evidence for a biphasic haemodynamic action.

Authors:  K J Hogg; R S Hornung; C A Howie; W S Hillis
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

2.  Inhibition of prolactin and aldosterone secretion by the dopamine derivative ibopamine.

Authors:  E Rolandi; G Marchetti; R Franceschini; V Cicchetti; R Gianrossi; V Cantoni; T Barreca
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.

Authors:  J M Henwood; P A Todd
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

4.  Investigation of a possible pharmacokinetic interaction between ibopamine and isosorbide-5-mononitrate.

Authors:  R A Lefebvre; G De Wilde; M T Rosseel; D Duprez; J De Sutter; F Pocchiari
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Acute effect of ibopamine and isosorbide mononitrate on blood volume distribution in congestive heart failure.

Authors:  N D Holman; O S Hoekstra; A B Groeneveld; A J Schneider; W G de Voogt; J van der Meer
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Haemodynamic evaluation of ibopamine in severe congestive heart failure.

Authors:  G C Reffo; M Turrin; A Gabellini; C Forattini
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure.

Authors:  P Ghirardi; B Brusoni; M Mangiavacchi; L Bianco; J Col; M Metra; L Dei Cas
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

8.  Peripheral hemodynamic effects of ibopamine in patients with congestive heart failure. A placebo-controlled, double-blind study.

Authors:  C Longhini; L Ansani; G F Musacci; S Aggio; E Baracca; T Toselli; P Ghirardi
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.